ASAM Pocket Guidelines and Patient Guide

Stimulant Use Disorder

ASAM Opioid Addiction Treatment GUIDELINES Apps and Pocket Guides brought to you courtesy of Guideline Central. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1519511

Contents of this Issue

Navigation

Page 10 of 29

11 Concurrent Management of StUD and ADHD 26. For patients with co-occurring StUD and ADHD, clinicians should address ADHD symptoms as part of the treatment of StUD (L-S). Clinicians should consider: a. prescribing psychostimulant medications to manage ADHD when the benefits of the medication outweigh the risks (L-S), b. prescribing non-stimulant medications to manage ADHD when the benefits of psychostimulant medications do not outweigh the risks (L-S), and c. behavioral approaches (L-S). 27. When prescribing psychostimulant medications to a patient with co-occurring StUD and ADHD, clinicians should consider: a. using extended-release formulations (CC-S); and b. maintaining a level of monitoring commensurate with the risk profile for the given medication and patient—monitoring may include pill counts, drug testing, more frequent clinical contact, and more frequent PDMP checks (CC-C). 28. For adolescent and young adult patients with co-occurring StUD and ADHD, clinicians should additionally consider: a. arranging for a parent, health professional (eg, trained school nurse), or other trusted adult to directly observe administration of the medication, especially if using a short-acting formulation (CC-S); and b. counseling families on the importance of safely storing and restricting access to controlled medications (CC-C).

Articles in this issue

view archives of ASAM Pocket Guidelines and Patient Guide - Stimulant Use Disorder